32 results on '"Frew, John W."'
Search Results
2. Granulomatous Disorders of the Skin
3. Understanding multi‐kinase inhibitor‐associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.
4. Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis
5. The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa
6. Reply to Tilotta and Bongiorno: Considering the role of resident cutaneous memory T‐cell suppression in providing durable atopic dermatitis remission
7. Academic dermatology in Australia and New Zealand between 2017 and 2022: A cross‐sectional bibliometric analysis
8. The impact of psoriasis biologic therapy on HIV viral load and CD4 + cell counts in HIV ‐positive individuals: A real‐world cohort study
9. Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
10. Angiotensin‐converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris
11. Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease
12. The pathogenesis of hidradenitis suppurativa: Evolving paradigms in a complex disease
13. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects
14. Target molecules for future hidradenitis suppurativa treatment
15. Ultrasound‐guided de‐roofing of epithelialised tunnels of hidradenitis suppurativa
16. What causes hidradenitis suppurativa ?—15 years after
17. A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa
18. The Asia Pacific Hidradenitis Suppurativa (APHiS) foundation: promoting hidradenitis suppurativa research in the Asia Pacific
19. Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets?
20. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa
21. Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta‐analysis
22. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa
23. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017
24. A retrospective cohort study of melanoma prevalence stratified by body site in a Regional Australian Population 1994‐2017: Site‐specific protective mechanisms
25. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
26. HLA-B*1502 haplotype screening prior to carbamazepine administration in individuals of south-east Asian ancestry nears cost-effectiveness in preventing severe cutaneous adverse drug reactions
27. Lichen amyloidosis involving the scalp
28. Adopting the orphan: The importance of recognising hidradenitis suppurativa as a systemic auto‐inflammatory disease
29. Fifty shades of yellow: a review of the xanthodermatoses
30. Adalimumab‐induced porokeratosis
31. Phenotypic heterogeneity implies heterogeneous pathogenic pathways in hidradenitis suppurativa
32. Categorizing immunofluorescence mapping in epidermolysis bullosa with pyloric atresia: Use as a broad prognostic indicator
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.